

Vicente E Villanueva

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8177171/publications.pdf>

Version: 2024-02-01

63
papers

2,499
citations

236612

25
h-index

205818

48
g-index

65
all docs

65
docs citations

65
times ranked

2475
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome. <i>New England Journal of Medicine</i> , 2018, 378, 1888-1897.	13.9	682
2	The epidemiology of drug-resistant epilepsy: A systematic review and meta-analysis. <i>Epilepsia</i> , 2018, 59, 2179-2193.	2.6	316
3	Safety, efficacy and outcome-related factors of perampanel over 12 months in a real-world setting: The FYDATA study. <i>Epilepsy Research</i> , 2016, 126, 201-210.	0.8	105
4	Perampanel in routine clinical use in idiopathic generalized epilepsy: The 12-month GENERAL study. <i>Epilepsia</i> , 2018, 59, 1740-1752.	2.6	86
5	Rational polytherapy with lacosamide in clinical practice: Results of a Spanish cohort analysis RELACOVA. <i>Epilepsy and Behavior</i> , 2012, 23, 298-304.	0.9	75
6	Perampanel in routine clinical use across Europe: Pooled, multicenter, observational data. <i>Epilepsia</i> , 2018, 59, 1727-1739.	2.6	67
7	Long-term safety and efficacy of eslicarbazepine acetate in patients with focal seizures: Results of the 1-year ESLIBASE retrospective study. <i>Epilepsy Research</i> , 2014, 108, 1243-1252.	0.8	63
8	BRIVA-LIFE-A multicenter retrospective study of the long-term use of brivaracetam in clinical practice. <i>Acta Neurologica Scandinavica</i> , 2019, 139, 360-368.	1.0	61
9	Adjunctive perampanel in adolescents with inadequately controlled partial-onset seizures: A randomized study evaluating behavior, efficacy, and safety. <i>Epilepsia</i> , 2016, 57, 1120-1129.	2.6	57
10	Efficacy of intravenous levetiracetam as an add-on treatment in status epilepticus: A multicentric observational study. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2011, 20, 60-64.	0.9	44
11	Comparison of two fMRI tasks for the evaluation of the expressive language function. <i>Neuroradiology</i> , 2010, 52, 407-415.	1.1	41
12	Long-term effects of adjunctive perampanel on cognition in adolescents with partial seizures. <i>Epilepsy and Behavior</i> , 2018, 83, 50-58.	0.9	38
13	Behavioral adverse events with brivaracetam, levetiracetam, perampanel, and topiramate: A systematic review. <i>Epilepsy and Behavior</i> , 2021, 118, 107939.	0.9	38
14	MRI Volumetry and Proton MR Spectroscopy of the Brain in Lafora Disease. <i>Epilepsia</i> , 2006, 47, 788-792.	2.6	37
15	Control of seizures in different stages of partial epilepsy: LACO-EXP, a Spanish retrospective study of lacosamide. <i>Epilepsy and Behavior</i> , 2013, 29, 349-356.	0.9	37
16	A step-wise approach for establishing a multidisciplinary team for the management of tuberous sclerosis complex: a Delphi consensus report. <i>Orphanet Journal of Rare Diseases</i> , 2019, 14, 91.	1.2	36
17	Efficacy and tolerability of zonisamide in idiopathic generalized epilepsy. <i>Epileptic Disorders</i> , 2009, 11, 061-066.	0.7	35
18	Factors influencing response to intravenous lacosamide in emergency situations: LACO-IV study. <i>Epilepsy and Behavior</i> , 2014, 36, 144-152.	0.9	34

#	ARTICLE	IF	CITATIONS
19	NEOPLASM study: Real-life use of lacosamide in patients with brain tumor-related epilepsy. <i>Epilepsy and Behavior</i> , 2016, 65, 25-32.	0.9	34
20	PERMIT study: a global pooled analysis study of the effectiveness and tolerability of perampanel in routine clinical practice. <i>Journal of Neurology</i> , 2022, 269, 1957-1977.	1.8	34
21	Guidance on Dravet syndrome from infant to adult care: Road map for treatment planning in Europe. <i>Epilepsia Open</i> , 2022, 7, 11-26.	1.3	32
22	Early Add-on Lacosamide in a Real-Life Setting: Results of the REALLY Study. <i>Clinical Drug Investigation</i> , 2015, 35, 121-131.	1.1	30
23	Euro-Esli: a European audit of real-world use of eslicarbazepine acetate as a treatment for partial-onset seizures. <i>Journal of Neurology</i> , 2017, 264, 2232-2248.	1.8	29
24	Behavioral disorder in people with an intellectual disability and epilepsy: A report of the Intellectual Disability Task Force of the Neuropsychiatric Commission of <sc>ILAE</sc>. <i>Epilepsia Open</i> , 2016, 1, 102-111.	1.3	27
25	Efficacy and safety of adjunctive perampanel in adolescent patients with epilepsy: Post hoc analysis of six randomized studies. <i>Epilepsy and Behavior</i> , 2020, 104, 106876.	0.9	27
26	Pooled efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal-onset seizures: Data from four double-blind placebo-controlled pivotal phase <sc>III</sc> clinical studies. <i>CNS Neuroscience and Therapeutics</i> , 2017, 23, 961-972.	1.9	25
27	Lacosamide monotherapy in clinical practice: A retrospective chart review. <i>Acta Neurologica Scandinavica</i> , 2018, 138, 186-194.	1.0	24
28	Probabilistic Distance for Mixtures of Independent Component Analyzers. <i>IEEE Transactions on Neural Networks and Learning Systems</i> , 2018, 29, 1161-1173.	7.2	24
29	Multichannel dynamic modeling of non-Gaussian mixtures. <i>Pattern Recognition</i> , 2019, 93, 312-323.	5.1	24
30	Pharmacokinetics, exposure-cognition, and exposure-efficacy relationships of perampanel in adolescents with inadequately controlled partial-onset seizures. <i>Epilepsy Research</i> , 2016, 127, 126-134.	0.8	23
31	Kaplan-Meier analysis on seizure outcome after epilepsy surgery: Do gender and race influence it?. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2008, 17, 314-319.	0.9	22
32	Practical guidance and considerations for transitioning patients from oxcarbazepine or carbamazepine to eslicarbazepine acetate - Expert opinion. <i>Epilepsy and Behavior</i> , 2015, 50, 46-49.	0.9	22
33	Dibenzazepine Agents in Epilepsy: How Does Eslicarbazepine Acetate Differ?. <i>Neurology and Therapy</i> , 2018, 7, 195-206.	1.4	21
34	Time to onset of cannabidiol (CBD) treatment effect in Lennox-Gastaut syndrome: Analysis from two randomized controlled trials. <i>Epilepsia</i> , 2021, 62, 1130-1140.	2.6	20
35	Quality of life in drug-resistant epilepsy: relationships with negative affectivity, memory, somatic symptoms and social support. <i>Journal of Psychosomatic Research</i> , 2018, 114, 31-37.	1.2	18
36	Psychiatric symptoms after temporal epilepsy surgery. A one-year follow-up study. <i>Epilepsy and Behavior</i> , 2017, 70, 154-160.	0.9	17

#	ARTICLE	IF	CITATIONS
37	Age at surgery as a predictor of cognitive improvements in patients with drug-resistant temporal epilepsy. <i>Epilepsy and Behavior</i> , 2017, 70, 10-17.	0.9	16
38	Time to onset of cannabidiol treatment effects in Dravet syndrome: Analysis from two randomized controlled trials. <i>Epilepsia</i> , 2021, 62, 2218-2227.	2.6	14
39	Management of Epilepsy in Oncological Patients. <i>Neurologist</i> , 2008, 14, S44-S54.	0.4	13
40	Eslicarbazepine acetate in post-stroke epilepsy: Clinical practice evidence from Euro-Esli. <i>Acta Neurologica Scandinavica</i> , 2020, 142, 563-573.	1.0	13
41	The number of anti-seizure medications mediates the relationship between cognitive performance and quality of life in temporal lobe epilepsy. <i>Epilepsy and Behavior</i> , 2021, 115, 107699.	0.9	13
42	Cortisol and trait anxiety as relevant factors involved in memory performance in people with drug-resistant epilepsy. <i>Epilepsy and Behavior</i> , 2019, 92, 125-134.	0.9	12
43	Effectiveness and Safety/Tolerability of Eslicarbazepine Acetate in Epilepsy Patients Aged ≥60 Versus <60 Years: A Subanalysis from the Euro-Esli Study. <i>Neurology and Therapy</i> , 2019, 8, 491-504.	1.4	12
44	The sentence verification task: a reliable fMRI protocol for mapping receptive language in individual subjects. <i>European Radiology</i> , 2010, 20, 2432-2438.	2.3	11
45	MONOZEB: Long-term observational study of eslicarbazepine acetate monotherapy. <i>Epilepsy and Behavior</i> , 2019, 97, 51-59.	0.9	10
46	Surgery and Electrical Stimulation in Epilepsy. <i>Neurologist</i> , 2007, 13, S29-S37.	0.4	8
47	Antiepileptic drug reduction and increased risk of stimulation-evoked focal to bilateral tonic-clonic seizure during cortical stimulation in patients with focal epilepsy. <i>Epilepsy and Behavior</i> , 2018, 80, 104-108.	0.9	8
48	Eslicarbazepine acetate in epilepsy patients with psychiatric comorbidities and intellectual disability: Clinical practice findings from the Euro-Esli study. <i>Journal of the Neurological Sciences</i> , 2019, 402, 88-99.	0.3	8
49	Safety, tolerability and effectiveness of transition to eslicarbazepine acetate from carbamazepine or oxcarbazepine in clinical practice. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2020, 75, 121-128.	0.9	8
50	Eslicarbazepine acetate as monotherapy in clinical practice: Outcomes from Euro-Esli. <i>Acta Neurologica Scandinavica</i> , 2019, 139, 49-63.	1.0	7
51	Perampanel for the treatment of patients with myoclonic seizures in clinical practice: Evidence from the PERMIT study. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2022, 100, 56-66.	0.9	7
52	Validation of the Spanish version of the Side Effect and Life Satisfaction Inventory in patients with epilepsy. <i>Epilepsy and Behavior</i> , 2009, 14, 96-101.	0.9	5
53	Initiating antiepilepsy treatment: An update of expert consensus in Spain. <i>Epilepsy and Behavior</i> , 2021, 114, 107540.	0.9	5
54	Mesial temporal sclerosis as a complication of hematologic cancer. <i>Journal of Neurology</i> , 2009, 256, 1759-1761.	1.8	4

#	ARTICLE	IF	CITATIONS
55	ESPERA study: Applicability of the new ILAE criteria for antiepileptic drug resistance of focal epilepsies in current clinical practice. <i>Epilepsy and Behavior</i> , 2012, 25, 166-169.	0.9	3
56	Bilateral inferior frontal language-related activation correlates with verbal recall in patients with left temporal lobe epilepsy and typical language distribution. <i>Epilepsy Research</i> , 2013, 104, 118-124.	0.8	3
57	Subthalamic lesion and paroxysmal tonic spasms. <i>Movement Disorders</i> , 2003, 18, 1401-1403.	2.2	2
58	Mixtures of independent component analyzers for microarousal detection. , 2014, , .		2
59	Initial monotherapy with eslicarbazepine acetate for the management of adult patients with focal epilepsy in clinical practice: a meta-analysis of observational studies. <i>International Journal of Neuroscience</i> , 2021, , 1-11.	0.8	2
60	Predictors of seizure freedom, response and retention after 12 months of treatment with eslicarbazepine acetate: A post-hoc analysis of the Euro-Esli study. <i>Epilepsy Research</i> , 2021, 174, 106653.	0.8	2
61	Reply to letter to the editor: “The psychiatric risks of temporal epilepsy surgery. What should patients be told?” by Bengi Kansu. <i>Epilepsy and Behavior</i> , 2018, 78, 313-314.	0.9	1
62	Drug load and memory during intracarotid amobarbital procedure in epilepsy. <i>Acta Neurologica Scandinavica</i> , 2021, 144, 585-591.	1.0	1
63	Clinical utility of Epitrack for differentiating profiles and patterns of post-surgical change in memory and quality of life in patients with drug-resistant epilepsy. <i>Applied Neuropsychology Adult</i> , 2022, , 1-12.	0.7	0